A case report: Long-term complete response of metastatic hepatocellular carcinoma obtained after discontinuation of 2-month sorafenib monotherapy

Abstract

A 69-year-old woman who had a history of chronic hepatitis C, autoimmune hemolytic anemia and myelodysplastic syndrome was treated with sorafenib at a daily dose of 400 mg for HCC with multiple lung metastases. Nonetheless, elevated serum tumor markers further increased (alpha fetoprotein from 121,100 to 348,660 ng/ml and protein induced by vitamin K absence/antagonist-II from 3435 to 29,357 mAU/ml), and lung metastatic lesions on chest X-ray showed no improvement after 2 months of sorafenib treatment. Sorafenib was discontinued because of adverse events with diarrhea, fatigue, and severe anemia due to bleeding from stomach telangiectasia. Hand–foot syndrome was mild. Thereafter, the tumor markers rapidly decreased to almost normal range, and the lung and liver tumors markedly shrunk and disappeared without any other cancer treatments. Her tumors remained in complete remission for 17 months until an intrahepatic recurrence occurred. This unique course of metastatic HCC indicated that antitumor mechanisms other than the direct anticancer effect of sorafenib contributed to tumor shrinkage.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. 1.

    Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    Article  Google Scholar 

  2. 2.

    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17.

    Article  Google Scholar 

  3. 3.

    Llovet JM, Ricci S, Mazzaferro V, SHARP Investigators Study Group, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

    CAS  Article  Google Scholar 

  4. 4.

    Rimola J, Díaz-González Á, Darnell A, et al. Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. Hepatology. 2018;67:612–22.

    CAS  Article  Google Scholar 

  5. 5.

    Wilhelm SM, Carter C, Tang L, et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–109.

    CAS  Article  Google Scholar 

  6. 6.

    Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.

    CAS  Article  Google Scholar 

  7. 7.

    Yada M, Masumoto A, Motomura K, et al. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World J Gastroenterol. 2014;20:12581–7.

    CAS  Article  Google Scholar 

  8. 8.

    Lamarca A, Abdel-Rahman O, Salu I, et al. Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib. Clin Transl Oncol. 2017;19:364–72.

    CAS  Article  Google Scholar 

  9. 9.

    Yau T, Yao TJ, Chan P, et al. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist. 2011;16:1270–9.

    CAS  Article  Google Scholar 

  10. 10.

    Shao YY, Lin ZZ, Hsu C, et al. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer. 2010;116:4590–6.

    CAS  Article  Google Scholar 

  11. 11.

    Arao T, Ueshima K, Matsumoto K, et al. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology. 2013;57:1407–15.

    CAS  Article  Google Scholar 

  12. 12.

    Kaibori M, Sakai K, Ishizaki M, et al. Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment. Oncotarget. 2016;7:49091–8.

    Article  Google Scholar 

  13. 13.

    Mizukami H, Kagawa T, Arase Y, et al. Complete response after short-term sorafenib treatment in a patient with lymph node metastasis of hepatocellular carcinoma. Case Rep Oncol. 2012;5:380–4.

    Article  Google Scholar 

  14. 14.

    Hagihara A, Teranishi Y, Kawamura E, et al. A complete response induced by 21-day sorafenib therapy in a patient with advanced hepatocellular carcinoma. Intern Med. 2013;52:1589–92.

    Article  Google Scholar 

  15. 15.

    Kermiche-Rahali S, Di Fiore A, Drieux F, et al. Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib. World J Surg Oncol. 2013;11:171.

    Article  Google Scholar 

  16. 16.

    Shiozawa K, Watanabe M, Ikehara T, et al. Sustained complete response of hepatocellular carcinoma with portal vein tumor thrombus following discontinuation of sorafenib: A case report. Oncol Lett. 2014;7:50–2.

    Article  Google Scholar 

  17. 17.

    Huan HB, Lau WY, Xia F, et al. Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma. World J Gastroenterol. 2014;20:14505–9.

    Article  Google Scholar 

  18. 18.

    Shiba S, Okusaka T, Ikeda M, et al. Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib. Hepatol Res. 2014;44:1268–76.

    CAS  Article  Google Scholar 

  19. 19.

    Liu D, Liu A, Peng J, et al. Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib. Eur J Med Res. 2015;20:12.

    Article  Google Scholar 

  20. 20.

    Katafuchi E, Takami Y, Wada Y, et al. Long-term maintenance of complete response after sorafenib treatment for multiple lung metastases from hepatocellular carcinoma. Case Rep Gastroenterol. 2015;9:285–90.

    Article  Google Scholar 

  21. 21.

    Kitajima T, Hatano E, Mitsunori Y, et al. Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection. Clin J Gastroenterol. 2015;8:300–5.

    Article  Google Scholar 

  22. 22.

    Kim TS, Kim JH, Kim BH, et al. Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review. Clin Mol Hepatol. 2017;23:340–6.

    Article  Google Scholar 

  23. 23.

    Nakano N, Kawaoka T, Aikata H, et al. Complete response to short-term sorafenib treatment alone for hepatocellular carcinoma with bone, lymph node, and peritoneum metastases. Hepatol Res. 2016;46:1402–8.

    Article  Google Scholar 

  24. 24.

    Li Q, Xu B, Fu L, et al. Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma. J Exp Clin Cancer Res. 2006;25:403–9.

    CAS  PubMed  Google Scholar 

  25. 25.

    Lin YY, Tan CT, Chen CW, et al. Immunomodulatory effects of current targeted therapies on hepatocellular carcinoma: implication for the future of immunotherapy. Semin Liver Dis. 2018;38:379–88.

    CAS  Article  Google Scholar 

  26. 26.

    Kalathil SG, Hutson A, Barbi J, et al. Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy. JCI Insight. 2019;4(15):e130116.

    Article  Google Scholar 

  27. 27.

    Cole WH. Efforts to explain spontaneous regression of cancer. J Surg Oncol. 1981;17:201–9.

    CAS  Article  Google Scholar 

  28. 28.

    Iwanaga T. Studies on cases of spontaneous regression of cancer in Japan in 2011, and of hepatic carcinoma, lung cancer and pulmonary metastases in the world between 2006 and 2011. Gan To Kagaku Ryoho. 2013;40:1475–87.

    PubMed  Google Scholar 

  29. 29.

    Tocci G, Conte A, Guarascio P, et al. Spontaneous remission of hepatocellular carcinoma after massive gastrointestinal haemorrhage. BMJ. 1990;300:641–2.

    CAS  Article  Google Scholar 

  30. 30.

    Kondo S, Okusaka T, Ueno H, et al. Spontaneous regression of hepatocellular carcinoma. Int J Clin Oncol. 2006;11:407–11.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Kazunori Ishige.

Ethics declarations

Conflict of interest

Ichinosuke Hyodo received lecture fees from company Taiho, Chugai, Daiichi-Sankyo and Yakult-Honsha. Suguru Hirose, Kazunori Ishige, Masamichi Yamaura, Tsuneo Mizui, Yoshiki Komatsu, Masaomi Nagase, Masashi Sato, Junji Hattori, Masato Endo, Naoyuki Hasegawa, and Kuniaki Fukuda declare that they have no conflict of interest.

Human rights

All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

Informed consent was obtained from all patients for being included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hirose, S., Ishige, K., Yamaura, M. et al. A case report: Long-term complete response of metastatic hepatocellular carcinoma obtained after discontinuation of 2-month sorafenib monotherapy. Clin J Gastroenterol (2020). https://doi.org/10.1007/s12328-020-01154-z

Download citation

Keywords

  • Hepatocellular carcinoma
  • Lung metastases
  • Sorafenib
  • Complete remission